Abstract:Since most dominant human mutations are single nucleotide substitutions<a href="/articles/s41591-019-0500-9#ref-CR1">1</a>,<a href="/articles/s41591-019-0500-9#ref-CR2">2</a>, we explored gene editing strategies to disrupt dominant mutations efficiently and selectively without affecting wild-type alleles. However, single nucleotide discrimination can be difficult to achieve<a href="/articles/s41591-019-0500-9#ref-CR3">3</a> because commonly used endonucleases, such as Streptococcus pyogenes Cas9 (SpCas9), can tolerate up to seven mismatches between guide RNA (gRNA) and target DNA. Furthermore, the protospacer-adjacent motif (PAM) in some Cas9 enzymes can tolerate mismatches with the target DNA<a href="/articles/s41591-019-0500-9#ref-CR3">3</a>,<a href="/articles/s41591-019-0500-9#ref-CR4">4</a>. To circumvent these limitations, we screened 14 Cas9/gRNA combinations for specific and efficient disruption of a nucleotide substitution that causes the dominant progressive hearing loss, DFNA36. As a model for DFNA36, we used Beethoven mice<a href="/articles/s41591-019-0500-9#ref-CR5">5</a>, which harbor a point mutation in Tmc1, a gene required for hearing that encodes a pore-forming subunit of mechanosensory transduction channels in inner-ear hair cells<a href="/articles/s41591-019-0500-9#ref-CR6">6</a>. We identified a PAM variant of Staphylococcus aureus Cas9 (SaCas9-KKH) that selectively and efficiently disrupted the mutant allele, but not the wild-type Tmc1/TMC1 allele, in Beethoven mice and in a DFNA36 human cell line. Adeno-associated virus (AAV)-mediated SaCas9-KKH delivery prevented deafness in Beethoven mice up to one year post injection. Analysis of current ClinVar entries revealed that ~21% of dominant human mutations could be targeted using a similar approach.

The Application of Genome Editing in Studying Hearing Loss.

The applications of CRISPR/Cas-mediated genome editing in genetic hearing loss

Gene editing based hearing impairment research and therapeutics

Genome and base editing for genetic hearing loss

[Applications of ZFN, TALEN and CRISPR/Cas9 Techniques in Disease Modeling and Gene Therapy].

Treatment of autosomal recessive hearing loss via in vivo CRISPR/Cas9-mediated optimized homology-directed repair in mice

Precise Detection of CRISPR-Cas9 Editing in Hair Cells in the Treatment of Autosomal Dominant Hearing Loss

Treatment of autosomal dominant hearing loss by in vivo delivery of genome editing agents

Prevention of acquired sensorineural hearing loss in mice by in vivo <i>Htra2</i> gene editing

Treatment of monogenic and digenic dominant genetic hearing loss by CRISPR-Cas9 ribonucleoprotein delivery in vivo

Development and application of CRISPR/Cas9 technologies in genomic editing.

Targeted genome editing restores auditory function in adult mice with progressive hearing loss caused by a human microRNA mutation

A Review of Application of Base Editing for the Treatment of Inner Ear Disorders

Prevention of acquired sensorineural hearing loss in mice by in vivo Htra2 gene editing

Preventing autosomal-dominant hearing loss in Bth mice with CRISPR/CasRx-based RNA editing

Template-independent genome editing in the <i>Pcdh15<SUP>av-3j</SUP></i> mouse, a model of human DFNB23 nonsyndromic deafness

Allele-specific gene editing prevents deafness in a model of dominant progressive hearing loss

Template-independent Genome Editing in the Pcdh15 Mouse, a Model of Human DFNB23 Nonsyndromic Deafness

Utilization of TALEN and CRISPR/Cas9 Technologies for Gene Targeting and Modification

In vivo outer hair cell gene editing ameliorates progressive hearing loss in dominant-negative Kcnq4 murine model

Utilization of TALEN and CRISPR/Cas9 technologies for gene targeting and modification.